Evercore ISI lowered the firm’s price target on Sarepta (SRPT) to $19 from $20 and keeps an In Line rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- FDA Commissioner Marty Makary resigns
- Trump Trade: Trump to suspend tariff-rate quotas on beef imports
- Trump Trade: U.S. plans AI security order without required model tests
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026